Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06634394 Clinical Landscape Report 2026
16 October 2026
NCT06634394 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06635681 Clinical Landscape Report 2026
16 October 2026
NCT06635681 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daratumumab in Plasma Cell Leukemia: NCT06636552 Clinical Landscape Report 2026
16 October 2026
NCT06636552 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VT-101(Jiangsu Wanbang) in Non-Muscle Invasive Bladder Neoplasms: NCT06632964 Clinical Landscape Report 2026
16 October 2026
NCT06632964 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
64Cu-LLP2A in Lymphoplasmacytic Lymphoma: NCT06636175 Clinical Landscape Report 2026
16 October 2026
NCT06636175 clinical landscape for Lymphoplasmacytic Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
EX02 CAR-T(Zeno Therapeutics) in Acute Myeloid Leukemia: NCT06642025 Clinical Landscape Report 2026
16 October 2026
NCT06642025 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCMA-GPRC5D CAR-T(Shenzhen University General Hospital) in Relapse multiple myeloma: NCT06644443 Clinical Landscape Report 2026
16 October 2026
NCT06644443 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Durvalumab in Bladder Cancer: ACTRN12624001245583 Clinical Landscape Report 2026
16 October 2026
ACTRN12624001245583 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab tirumotecan in Non-Muscle Invasive Bladder Neoplasms: NCT06637423 Clinical Landscape Report 2026
16 October 2026
NCT06637423 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
OL-101 in Multiple Myeloma: NCT06644118 Clinical Landscape Report 2026
16 October 2026
NCT06644118 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06643962 Clinical Landscape Report 2026
16 October 2026
NCT06643962 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DR-0201 in Rheumatic Diseases: NCT06647069 Clinical Landscape Report 2026
16 October 2026
NCT06647069 clinical landscape for Rheumatic Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.